drugset / Trial / NCT03600766
Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study
RandomizedParallel-groupOpen-labelTreatment
Summary
To study the impact of mirabegron, a B3-adrenoceptor agonist, in the treatment of ED in patients with LUTS secondary to BPH and concomitant ED.
Timeline
- Start
- 2018-08-01
- Primary completion
- 2020-01-01
- Completion
- 2020-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mirabegron | Other / unclassified | 50 g | Oral |
| Comparator | toltordine | Unknown | 4 mg | Oral |
| Comparator | Tamsulosin | Other / unclassified | 0.4 mg | Oral |